NOTTINGHAM, UK – 27 April, 2021 – Life Science Newswire – Sygnature Discovery, a world-leading integrated discovery and pre-clinical solutions provider, has established a new office presence in South San Francisco’s biotech hub at Oyster Point, where it can better serve current and future clients on the US west coast.
The new office presence comes in the wake of another year of impressive growth for the company, which has recently expanded operations at its headquarters in Nottingham, UK, as well as opening a second co-located integrated drug discovery site at the world-class research campus at Alderley Park, UK.
Sygnature established its first US office in 2019 in the heart of the Cambridge–Boston biotech hub in Massachusetts, and this expansion of its US presence with a second office will help meet growing demand from its US customers, which range from major pharma through to small seed-funded biotechs.
“Our very first client was actually from the US,” said Simon Hirst, Sygnature’s CEO and founder “and it remains a very significant market for us, both now and in our future strategy. It’s fantastic to have a base on the west coast, and in such a vibrant hub for the life sciences community.
“Our approach to drug discovery is based on true collaboration and partnership with our clients and having a physical presence near to many of them helps us to work the way we believe in, strengthening those ties and relationships that lead to success.”
The new office is located on Gateway Boulevard, Oyster Point, in South San Francisco – often nicknamed “the Birthplace of Biotechnology” and home to one of the largest biotech clusters in the world, with over 200 biotech companies, and 11.5 million square feet of biotech space across 500 acres.
Sygnature offers high-quality, fully-integrated drug discovery and pre-clinical services to customers around the world, as well as flexible, stand-alone solutions in medicinal chemistry, in vitro biology, computational chemistry, DMPK and pre-clinical experimental services.
- ENDS -
NOTES TO EDITORS
About Sygnature Discovery
Sygnature Discovery is a leading independent integrated drug discovery and non-clinical services company. Private equity-backed since 2017, the company operates fully enabled research facilities in Nottingham and Alderley Park, UK, housing nearly 400 research scientist (over 80% of whom hold a PhD), and has an office presence in Cambridge, MA, and South San Francisco, CA, in the USA.
Their experienced drug-hunters possess all the professional skills and know-how required to undertake the most demanding of research programmes, and drive them from target validation through hit identification, hit-to-lead and lead optimisation to pre-clinical development candidate. Sygnature’s in vivo pharmacology arm was formed by the incorporation of RenaSci, acquired in 2018, into Sygnature’s fully-integrated drug discovery platform. In 2020 Sygnature added to this with the acquisitions of in vivo oncology firm Alderley Oncology and DMPK provider XenoGesis.
Since 2011, 34 compounds discovered by Sygnature for customers have entered pre-clinical development and, so far, 17 of these have progressed to clinical trials (Phases I, II and III). In 2017, Sygnature Discovery received the prestigious Queen’s Award for Enterprise for International Trade, and in the last year has won both the Medilink Outstanding Achievement Award and the Bionow Company of the Year Award.
For further information, visit www.sygnaturediscovery.com